The U.S. Food and Drug Administration (FDA) approved Ripretinib on May 15, 2020, for the treatment of advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib.

HUADONG MEDICINE Reports Encouraging Phase I Outcomes for New Oral GLP-1 Receptor Agonist HDM1002.

The U.S. Food and Drug Administration (FDA) approved Selpercatinib on May 8, 2020, under an accelerated approval process.

Star Therapeutics Unveils Clinical Findings on VGA039, an Injectable Therapy for Von Willebrand Disease (VWD).

The FDA granted approval for capmatinib on May 6, 2020. Capmatinib is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed with surgery.

Arrowhead Pharmaceuticals to Progress RNAi Therapy Plozasiran into Phase 3 CAPITAN Trial for Cardiovascular Results.

The FDA approved Darzalex Faspro for the treatment of multiple myeloma and light chain amyloidosis in adults on May 1, 2020.

Werewolf Therapeutics Presents Early Safety and Effectiveness Results from Phase 1 Study of WTX-330 in Patients with Advanced Solid Tumors or Non-Hodgkin Lymphoma.

The FDA approved Bafiertam for the treatment of relapsing forms of multiple sclerosis (MS) on April 28, 2020.

EZHARMIA® Receives Approval in Japan as the First Dual EZH1 and EZH2 Blocker for Peripheral T-Cell Lymphoma Therapy.

MenQuadfi, a meningococcal conjugate vaccine, is FDA approved. The FDA granted approval for MenQuadfi on April 23, 2020.

vTv Therapeutics Announces Enrollment of First Participant in CATT1 Key Study for Cadisegliatin in Type 1 Diabetes.